LazyNews
NORMAL
Technology

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s - CNBC

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.

Share:
The next generation of blockbuster obesity drugs isn't trying to replace GLP-1 medicines. Instead, drugmakers are developing treatments that can complement existing drugs and push weight loss furthe… [+7091 chars]

Community

Comments

Share your perspective. Thoughtful contributions make LazyNews useful.

0 comments

Log in to join the discussion.

Loading comments…